Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 6/20 | 0.49 |
| ▸ | FLT3 | P36888 | 4/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CCNH | P51946 | 1/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.49 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.48 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.46 |
| ▸ | CDK9 | P50750 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4453332 | 0.85 | JAK2 (0.73) | JAK2JAK3CDK2HDAC1HDAC6 | |
| SCHEMBL4603101 | 0.84 | JAK2 (0.55) | JAK2JAK3CDK2FLT3CCNE1 | |
| SCHEMBL4558034 | 0.80 | JAK2 (0.58) | JAK2JAK3CDK2FLT3CCNE1 | |
| SCHEMBL4583374 | 0.75 | JAK2 (0.54) | JAK2JAK3CDK2FLT3CCNE1 | |
| Water SCHEMBL27898069 | 0.74 | SMG1 (0.55) | JAK2JAK3CDK2FLT3CCNE1 | |
| SCHEMBL12800942 | 0.72 | JAK2 (0.51) | JAK2JAK3CDK2FLT3CCNE1 | |
| SCHEMBL4385969 | 0.72 | JAK2 (0.71) | JAK2JAK3HDAC1HDAC6 | |
| SCHEMBL34463169 | 0.72 | JAK2 (0.65) | JAK2JAK3CDK2FLT3CCNE1 | |
| SCHEMBL4385527 | 0.71 | JAK2 (0.76) | JAK2JAK3HDAC1HDAC6PLK1 | |
| SCHEMBL4558054 | 0.71 | JAK2 (0.69) | JAK2JAK3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885CDK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.